NRX Pharmaceuticals, Inc. Business Combination, Contingent Consideration, Liability, Current
NRX Pharmaceuticals, Inc. (NRXP) had Business Combination, Contingent Consideration, Liability, Current of $2.48 million as of 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent · last filed 2023-03-31
- 2022-03-31: Business Combination, Contingent Consideration, Liability, Current $2.48M.
- 2021-12-31: Business Combination, Contingent Consideration, Liability, Current $4.58M.
- 2021-09-30: Business Combination, Contingent Consideration, Liability, Current $26.28M.
- 2021-06-30: Business Combination, Contingent Consideration, Liability, Current $25.87M.
| Period end | Business Combination, Contingent Consideration, Liability, Current |
|---|---|
| 2022-03-31 | $2.48M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $4.58M 10-K · filed 2023-03-31 |
| 2021-09-30 | $26.28M 10-Q/A · filed 2022-08-12 |
| 2021-06-30 | $25.87M 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |